Skip to main content

Galcanezumab-gnlm (Emgality) Shortage

Last Updated: December 22, 2023
Status: Current

Products Affected - Description
    • Emgality subcutaneous injection, Lilly USA, LLC, 100 mg/mL, 1 mL prefilled syringe, 3 count, NDC 00002-3115-09
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL pen, 1 count, NDC 00002-1436-11
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL pen, 2 count, NDC 00002-1436-27
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL prefilled syringe, 1 count, NDC 00002-2377-11
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL prefilled syringe, 2 count, NDC 00002-2377-27
Reason for the Shortage
    • Lilly has Emgality on shortage due to increased demand.
Available Products
    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Lilly has all Emgality presentations on intermittent back order and the company is releasing product as it becomes available.

Updated

Created December 22, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.